Z17.421
Hormone receptor negative with human epidermal growth factor receptor 2 negative status
Clinical Classification Guidelines
Inclusion Terms
- HR- with HER2-
- TNBC
- Triple negative breast cancer
Medical Intelligence & Overview
Triple negative breast cancer (TNBC) is a unique form of breast cancer characterized by the absence of three key receptors on the surface of the cancer cells. Specifically, it lacks estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). The ICD-10 code Z17.421 is used to classify cases where the tumor is hormone receptor-negative and HER2-negative, identifying it as a subtype of breast cancer with distinct features and treatment considerations. This type of breast cancer is known for its aggressive behavior and limited targeted therapy options, making early detection and comprehensive management essential.
Causes & Symptoms
Clinical Causes: Genetic mutations that influence cell growth and division Inherited genetic factors, such as BRCA1 mutations Previous exposure to radiation or certain carcinogens Lifestyle factors, including age, obesity, and alcohol consumption Hormonal influences, although triple-negative subtypes are hormone receptor-negative
Key Symptoms: A lump or mass in the breast or underarm area Changes in the size, shape, or appearance of the breast Skin changes over the breast, such as dimpling or redness Nipple abnormalities, including inversion or discharge Unexplained pain or tenderness in the breast or nipple Swelling or discomfort in the breast or nearby lymph nodes
Diagnostic & Treatment
Diagnosis Path: Physical examination of the breasts and lymph nodes Imaging tests such as mammography, ultrasound, or MRI to detect and evaluate the tumor Biopsy procedures (fine-needle aspiration, core needle biopsy, or surgical biopsy) to obtain tissue samples Laboratory analysis of the biopsy to determine the status of ER, PR, and HER2 receptors Additional tests like genetic profiling may be performed to identify risk factors or specific gene mutations
Treatment Protocols: Surgery to remove the tumor, which may involve lumpectomy or mastectomy Chemotherapy, which is often the main systemic treatment due to the lack of targeted therapies Radiation therapy to eliminate residual cancer cells after surgery Immunotherapy, which has shown promise in some cases of TNBC Clinical trials exploring new treatments and drug combinations Supportive care to manage side effects and improve quality of life
Clinical Advice & FAQs
Billing Guidance
Is Z17.421 a billable ICD-10 code?
Yes, Z17.421 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report Z17.421?
Clinical documentation must specify the nature of Hormone receptor negative with human epidermal growth factor receptor 2 negative status and any associated comorbidities for accurate reporting.
Cite this Clinical Reference